Aurealis Therapeutics will share the results of its DIAMEND AUP-16 Phase 2 clinical trial for non-healing DFUs at EWMA 2026

Symposium on Advanced Wound Care 2025

Start: 30 April, 2025
End: 4 May, 2025
Location: Texas, USA

Symposium on Advanced Wound Care (SAWC) Spring, held April 30–May 4, 2025, in Grapevine, TX. Juha Yrjänheikki (CEO) and Laurent Décory (COO) participated to meet with Advanced Wound Care companies to discuss potential partnerships, as well as with clinicians and KOLs to discuss clinical plans.

Share the event:

other recent events:

Week of Strategic Meetings in China 2025

During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners. The visit aimed to strengthen strategic relationships that support the development and commercialisation of Aurealis’ multi-target cell and gene therapy candidates, AUP-16 for chronic

World Drug Safety Congress Europe 2025

Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands. As Europe’s leading forum for drug safety and pharmacovigilance, the congress provides an important platform to exchange knowledge and address the most pressing challenges faced by safety professionals. At Aurealis Therapeutics, patient safety is central to